Horizon Therapeutics (HPTX) & Its Peers Head-To-Head Survey

Horizon Therapeutics (NASDAQ: HPTX) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Horizon Therapeutics to similar businesses based on the strength of its analyst recommendations, dividends, profitability, earnings, valuation, institutional ownership and risk.

Analyst Recommendations

This is a summary of recent ratings and price targets for Horizon Therapeutics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Horizon Therapeutics 0 0 0 0 N/A
Horizon Therapeutics Competitors 169 837 1832 61 2.62

As a group, “Biopharmaceuticals” companies have a potential downside of 0.22%. Given Horizon Therapeutics’ competitors higher probable upside, analysts plainly believe Horizon Therapeutics has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Horizon Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Horizon Therapeutics N/A N/A -1,533.00
Horizon Therapeutics Competitors $613.74 million $60.23 million 66.08

Horizon Therapeutics’ competitors have higher revenue and earnings than Horizon Therapeutics. Horizon Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

43.5% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 14.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Horizon Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Horizon Therapeutics 23.13% 21.30% 15.42%
Horizon Therapeutics Competitors -13,448.98% -53.99% -24.38%

Summary

Horizon Therapeutics competitors beat Horizon Therapeutics on 5 of the 8 factors compared.

About Horizon Therapeutics

Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company’s products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply